Investigation of willingness in individualized medication of voriconazole in fungal infectious patients
10.13699/j.cnki.1001-6821.2017.05.019
- VernacularTitle:真菌感染患者对伏立康唑个体化用药的意愿调查
- Author:
Xiao-Han XU
1
;
Ken CHEN
;
Hao SUN
;
Tao-Tao WANG
;
Miao YAN
;
Hai-Ying JIN
;
Shi-Hao JIANG
;
Ai-Ping WEN
;
Yi-Meng GUO
;
Lin HUANG
;
Suo-Di ZHAI
Author Information
1. 北京大学第三医院药剂科
- Keywords:
voriconazole;
individualized medication;
perception and willingness;
guideline
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(5):456-458,466
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the perception and willingness of patients on individualized medication of voriconazole,to discuss the factors influencing patients' decision-making,and to support the development of the practice guideline for individualized medication of voriconazole.Methods A cross-sectional study involving various types of patients in 9 hospitals was conducted by questionnaire to evaluate the perception and willingness on therapeutic drug monitoring (TDM) of voriconazole and CYP2C19 genotype testing.Results A total of 119 patients were involved,including 24 (20.17％) children.Ninety five (79.83 ％) patients thought voriconazole TDM was necessary during the treatment of fungal infections.There was a significant difference on preference towards voriconazole TDM between patients who had received voriconazole TDM,before and patients who had never taken voriconazole TDM (100％ vs 75.76％,P ＜ 0.05).Fifty four patients (45.38％) agreed on CYP2C19 gene test.For this question,there was a significant difference among patients with different types of medicare (P ＜ 0.05).The ranking of factors that contributed to the 2 decision-making was consistent (P ＜0.05).The clinical efficacy was the most important factor (mean rank 3.46 and 3.87,respectively),while cost (mean rank 1.89) and potential benefit (mean rank 2) was the least important factor for the 2 decision-making,respectively.Conclusion There was a significant variance among different types of patients on preferences towards voriconazole TDM and CYP2C19 genotype testing,which should be considered for clinicians to make clinical decisions.The perception and willingness of patients should also be considered during the development of clinical practice guidelines and clinical practice.
